52 The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial

DOI: 10.1136/jitc-2024-sitc2024.0052 Publication Date: 2024-11-05T14:58:58Z